IFRX - inflarx.de Debt to Book Capitalization Ratio

Graphic logo of InflaRx (IFRX)

While government subsidies minimize the capital risks for InflaRx N.V. (IFRX), attracting leading German immunologists requires significant investment. The debt-to-book capitalization ratio history on GURU.Markets helps balance these factors, with the indicator currently standing at 0.01. Financial stability is further bolstered by the implementation of laboratory robotics, which automates the discovery of new therapeutic molecules.

IFRX (InflaRx) Debt to Book Value history from 07/04/2022 to 10/27/2026
Core merchandise of inflarx.de

This ratio reflects the relationship between total liabilities and equity, determining the business's degree of dependence on borrowed funds. An increase in this metric signals rising financial risks and a potential loss of stability. By analyzing the company's debt-to-book capitalization ratio, an investor can track leverage dynamics. For InflaRx N.V. (IFRX), balancing liabilities is critical when financing clinical trials. Optimizing borrowings will ensure maximum margins during the commercialization of proprietary antibodies.

Who InflaRx N.V. competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Debts to Book Value Zenas Bio ZBIO|Debts to Book Capitalization IMNM (Immunome Corp)|GOSS: Debts to Net Assets|Debt to Book Capitalization Ratio KalVista Pharmaceuticals|septerna.com (SEPN) - Debt to Book Value Ratio|Debts to Book Capitalization Pieris Pharmaceuticals, Inc. PVLA|Debts to Book Capitalization Ratio SVRA|Debt to Book Capitalization Ratio Rigel Pharmaceuticals Inc (RIGL)|Debt to Book Capitalization Ratio AnaptysBio Inc. (ANAB)|Debts to Book Capitalization ATXS (Astria Therapeutics)|engene.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio RAPT Therapeutics, Inc. (RAPT)|Aerovate Therapeutics Inc (JBIO) - Debt to Net Assets Ratio|Debt to Book Value Aclaris|Debt to Book Value Ratio Kyverna Therapeutics, Inc|TLSA - Debt to Book Value|Debt to Net Assets Ratio CABA|Debt to Book Capitalization Ratio Ventyx Biosciences, Inc. VTYX|Debt to Book Value Ratio Theratechnologies, Inc. THTX|Debt to Book Value AVTX|ELDN - Debts to Net Assets|AGEN - Debt to Book Value|climbbio.com (CLYM) - Debt to Book Capitalization Ratio|Zura Bio Limited - Debt to Book Value|aTyr Pharma Inc (ATYR) - Debts to Net Assets|ADAG: Debts to Book Capitalization|Debts to Net Assets Ikena Oncology, Inc.|STTK - Debts to Book Capitalization|Debts to Book Capitalization Ratio EQ (equilliumbio.com)|Debt to Book Capitalization Ratio Connect Biopharma Holdings Limited|IMUX - Debt to Net Assets Ratio|Atara Biotherapeutics Inc (ATRA) - Debt to Book Value|XFOR: Debt to Book Value Ratio|Debt to Book Capitalization Ratio adicetbio.com (ACET)|Celularity (CELU) - Debts to Book Capitalization Ratio|INMB - Debts to Book Capitalization|Debt to Net Assets Ratio Barinthus Biotherapeutics PLC|Debts to Book Capitalization KZR|Debts to Book Capitalization SABS (SAB Biotherapeutics Inc)|Debt to Book Capitalization Ratio Akari Therapeutics|Enlivex Therapeutics Ltd - Debt to Net Assets Ratio|QTTB: Debt to Book Capitalization Ratio|GOVX - Debt to Book Value|EDSA: Debts to Book Capitalization|Debts to Book Capitalization iBio Corporation|CARM - Debt to Book Value|Debt to Net Assets Ratio xtlbio.com|BOLT (Bolt Biotherapeutics) - Debts to Book Capitalization|Debts to Net Assets HCWB (hcwbiologics.com)|Aptevo Therapeutics Inc. - Debt to Book Capitalization Ratio|AIM ImmunoTech, Inc. - Debt to Book Value|ADTX: Debt to Book Capitalization Ratio|gribio.com (GRI) - Debt to Book Value|XRTX: Debt to Book Value|HIND (Vyome Holdings Inc.) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Revelation Bio (REVB)|Debt to Book Value Ratio Indaptus Corp|Scinai Immunotherapeutics - Debts to Book Capitalization|Debts to Book Value calcimedica.com (CALI)|Debts to Book Capitalization AFMD|Allakos Inc - Debts to Net Assets|HOOKIPA (HOOK) - Debt to Book Capitalization Ratio|IGMS - Debt to Book Value Ratio|Debts to Book Capitalization iTeos Therapeutics (ITOS)|OCEA (oceanbiomedical.com) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio TC BioPharm|Debt to Book Capitalization Ratio Third Harmonic Bio Inc.